Figulla H R, Stille-Siegener M, Mall G, Heim A, Kreuzer H
Department of Internal Medicine, University of Göttingen, Germany.
J Am Coll Cardiol. 1995 Apr;25(5):1170-5. doi: 10.1016/0735-1097(94)00517-t.
Endomyocardial biopsy samples from patients with idiopathic dilated cardiomyopathy were screened for the presence of enterovirus genome. Patients with enterovirus-positive samples were further studied with regard to disease course, histologic variables and response to interferon-alpha treatment.
Studies of patients with idiopathic dilated cardiomyopathy have reported widely divergent clinical outcomes, suggesting that there is no unique underlying pathogenetic mechanism.
Five left ventricular endomyocardial biopsy samples were screened for the presence of the enterovirus genome by an established in situ hybridization technique in combination with a histologic, histomorphometric and immunohistologic workup. The course of the disease was then prospectively followed for up to 50 months. Virus-positive patients whose condition deteriorated were treated with interferon-alpha.
Of 77 patients, 20 (26%) had enterovirus-positive and 57 (74%) enterovirus-negative biopsy samples. During a mean follow-up period of 25.8 +/- 13.7 months, 1 patient in the enterovirus-positive group and 11 in the enterovirus-negative group died. Four patients in the enterovirus-negative group underwent heart transplantation (p < 0.05). The surviving 19 enterovirus-positive patients had a decrease in mean left ventricular end-diastolic diameter from 66 to 61 mm (p < 0.05) and a mean increase in left ventricular ejection fraction from 0.35 to 0.43 (p < 0.05). In contrast, enterovirus-negative patients had no significant change in end-diastolic diameter or left ventricular ejection fraction. Four patients in the enterovirus-positive group whose condition deteriorated were treated with a 6-month course of subcutaneous interferon-alpha (3 x 10(6) U every second day). This treatment induced hemodynamic improvement in all four patients and eliminated the persistent enteroviral infection in two.
Enterovirus-positive patients have a better heart transplantation-free survival rate and hemodynamic course, with fewer histologic changes, than do enterovirus-negative patients. In addition, enterovirus-positive patients respond favorably to interferon-alpha treatment. These observations indicate that myocardial enteroviral infection with associated left ventricular dysfunction is a distinct disease entity with a benign course.
对特发性扩张型心肌病患者的心内膜心肌活检样本进行筛查,以检测是否存在肠道病毒基因组。对肠道病毒检测呈阳性的患者,进一步研究其病程、组织学变量以及对α干扰素治疗的反应。
对特发性扩张型心肌病患者的研究报告了广泛不同的临床结果,这表明不存在独特的潜在致病机制。
采用一种成熟的原位杂交技术,结合组织学、组织形态计量学和免疫组织学检查,对5份左心室心内膜心肌活检样本进行肠道病毒基因组检测。然后对患者的病情进行前瞻性随访,最长随访50个月。对病情恶化的病毒阳性患者给予α干扰素治疗。
77例患者中,20例(26%)的活检样本肠道病毒检测呈阳性,57例(74%)呈阴性。在平均25.8±13.7个月的随访期内,肠道病毒阳性组有1例患者死亡,肠道病毒阴性组有11例患者死亡。肠道病毒阴性组有4例患者接受了心脏移植(p<0.05)。存活的19例肠道病毒阳性患者的平均左心室舒张末期直径从66毫米降至61毫米(p<0.05),左心室射血分数平均从0.35升至0.43(p<0.05)。相比之下,肠道病毒阴性患者的舒张末期直径或左心室射血分数无显著变化。肠道病毒阳性组中4例病情恶化的患者接受了为期6个月的皮下α干扰素治疗(每两天3×10⁶单位)。该治疗使所有4例患者的血流动力学得到改善,其中2例患者的持续性肠道病毒感染被清除。
与肠道病毒阴性患者相比,肠道病毒阳性患者的无心脏移植生存率更高,血流动力学病程更好,组织学变化更少。此外,肠道病毒阳性患者对α干扰素治疗反应良好。这些观察结果表明,伴有左心室功能障碍的心肌肠道病毒感染是一种病程良性的独特疾病实体。